^
    2ms
    Zencurix to present study on early detection of liver cancer at ESMO 2024 [Google translation] (Medipana)
    "Gencurix announced on the 11th that it will present the results of a study proving the effectiveness of 'HEPA eDX', a new molecular genetic testing method for early diagnosis of liver cancer, at the 2024 European Society for Medical Oncology (ESMO 2024), to be held from the 13th to the 17th....In this study, HEPA eDX tests were performed on cell lines and tissues of various cancers including liver cancer, as well as the blood of actual liver cancer patients, and the results confirmed that the methylation level of the biomarker was significantly higher in liver cancer than in other cancers." "
    Preclinical • Clinical
    |
    HEPA eDX
    4ms
    Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening (ESMO 2024)
    The HEPA eDX test has demonstrated outstanding sensitivity and specificity, establishing its potential as a superior alternative to current HCC screening methods such as AFP.
    Circulating tumor DNA • Epigenetic controller
    |
    AFP (Alpha-fetoprotein)
    |
    HEPA eDX
    3years
    Gencurix, liquid biopsy liver cancer early diagnosis 'Hepa eDX' clinical trial (Health Korea News)
    "Gencurix...begins clinical trials of HEPA eDX, a liquid biopsy liver cancer early diagnosis test. If successful in clinical trials, HEPA eDX is expected to become the world's first commercially successful liver cancer early diagnosis product...The company aims to complete clinical trials by the first quarter of next year and complete approval from the Ministry of Food and Drug Safety within the first half of next year. The strategy is to make every effort to prepare for the official release at the same time as the approval."
    New trial
    |
    HEPA eDX